Profile of plecanatide in the treatment of chronic idiopathic constipation: Design, development, and place in therapy

Amol Sharma, Anam Asif Herekar, Jigar Bhagatwala, Satish Sanku Chander Rao

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Constipation is a multifactorial disorder that can cause significant psychological distress to patients and economic burden on the health care system. Many patients are not satisfied with their current established treatment, highlighting the need for new and improved therapeutic options. Guanylate cyclase-C (GC-C)/cyclic guanosine monophosphate agonists have emerged as a safe and efficacious class of drugs for the treatment of chronic idiopathic constipation (CIC). Plecanatide, a second-in-class, US FDA-approved, synthetic GC-C agonist, has recently been approved in the US for the treatment of irritable bowel syndrome with constipation at doses of 3 and 6 mg and CIC at the 3 mg dosage. In this study, we summarize the design of this novel 16-amino acid uroguanylin analog, drug development through Phase I, II, and III clinical studies, and its role in the treatment of CIC.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalClinical and Experimental Gastroenterology
Volume12
DOIs
StatePublished - Jan 1 2019

Fingerprint

Constipation
Guanylate Cyclase
Therapeutics
Irritable Bowel Syndrome
Cyclic GMP
Pharmaceutical Preparations
Economics
plecanatide
Psychology
Delivery of Health Care
Amino Acids

Keywords

  • Constipation
  • Plecanatide
  • Uroguanylin

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Profile of plecanatide in the treatment of chronic idiopathic constipation : Design, development, and place in therapy. / Sharma, Amol; Herekar, Anam Asif; Bhagatwala, Jigar; Rao, Satish Sanku Chander.

In: Clinical and Experimental Gastroenterology, Vol. 12, 01.01.2019, p. 31-36.

Research output: Contribution to journalReview article

@article{31257c4361ce46cbab5f33a1ee6bc467,
title = "Profile of plecanatide in the treatment of chronic idiopathic constipation: Design, development, and place in therapy",
abstract = "Constipation is a multifactorial disorder that can cause significant psychological distress to patients and economic burden on the health care system. Many patients are not satisfied with their current established treatment, highlighting the need for new and improved therapeutic options. Guanylate cyclase-C (GC-C)/cyclic guanosine monophosphate agonists have emerged as a safe and efficacious class of drugs for the treatment of chronic idiopathic constipation (CIC). Plecanatide, a second-in-class, US FDA-approved, synthetic GC-C agonist, has recently been approved in the US for the treatment of irritable bowel syndrome with constipation at doses of 3 and 6 mg and CIC at the 3 mg dosage. In this study, we summarize the design of this novel 16-amino acid uroguanylin analog, drug development through Phase I, II, and III clinical studies, and its role in the treatment of CIC.",
keywords = "Constipation, Plecanatide, Uroguanylin",
author = "Amol Sharma and Herekar, {Anam Asif} and Jigar Bhagatwala and Rao, {Satish Sanku Chander}",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/CEG.S145668",
language = "English (US)",
volume = "12",
pages = "31--36",
journal = "Clinical and Experimental Gastroenterology",
issn = "1178-7023",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Profile of plecanatide in the treatment of chronic idiopathic constipation

T2 - Design, development, and place in therapy

AU - Sharma, Amol

AU - Herekar, Anam Asif

AU - Bhagatwala, Jigar

AU - Rao, Satish Sanku Chander

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Constipation is a multifactorial disorder that can cause significant psychological distress to patients and economic burden on the health care system. Many patients are not satisfied with their current established treatment, highlighting the need for new and improved therapeutic options. Guanylate cyclase-C (GC-C)/cyclic guanosine monophosphate agonists have emerged as a safe and efficacious class of drugs for the treatment of chronic idiopathic constipation (CIC). Plecanatide, a second-in-class, US FDA-approved, synthetic GC-C agonist, has recently been approved in the US for the treatment of irritable bowel syndrome with constipation at doses of 3 and 6 mg and CIC at the 3 mg dosage. In this study, we summarize the design of this novel 16-amino acid uroguanylin analog, drug development through Phase I, II, and III clinical studies, and its role in the treatment of CIC.

AB - Constipation is a multifactorial disorder that can cause significant psychological distress to patients and economic burden on the health care system. Many patients are not satisfied with their current established treatment, highlighting the need for new and improved therapeutic options. Guanylate cyclase-C (GC-C)/cyclic guanosine monophosphate agonists have emerged as a safe and efficacious class of drugs for the treatment of chronic idiopathic constipation (CIC). Plecanatide, a second-in-class, US FDA-approved, synthetic GC-C agonist, has recently been approved in the US for the treatment of irritable bowel syndrome with constipation at doses of 3 and 6 mg and CIC at the 3 mg dosage. In this study, we summarize the design of this novel 16-amino acid uroguanylin analog, drug development through Phase I, II, and III clinical studies, and its role in the treatment of CIC.

KW - Constipation

KW - Plecanatide

KW - Uroguanylin

UR - http://www.scopus.com/inward/record.url?scp=85062706493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062706493&partnerID=8YFLogxK

U2 - 10.2147/CEG.S145668

DO - 10.2147/CEG.S145668

M3 - Review article

AN - SCOPUS:85062706493

VL - 12

SP - 31

EP - 36

JO - Clinical and Experimental Gastroenterology

JF - Clinical and Experimental Gastroenterology

SN - 1178-7023

ER -